Long‐term follow‐up of the thyroid gland after treatment with 131I‐Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance. Issue 11 (6th July 2013)
- Record Type:
- Journal Article
- Title:
- Long‐term follow‐up of the thyroid gland after treatment with 131I‐Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance. Issue 11 (6th July 2013)
- Main Title:
- Long‐term follow‐up of the thyroid gland after treatment with 131I‐Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance
- Authors:
- Clement, S.C.
van Eck‐Smit, B.L.F.
van Trotsenburg, A.S.P.
Kremer, L.C.M.
Tytgat, G.A.M.
van Santen, H.M. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24681-sec-0001" sec-type="section"> <title>Background</title> <p>Thyroid dysfunction has been reported in up to 52% of patients 1.4 years after treatment with <sup>131</sup>I‐Metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), despite the use of potassium‐iodide (KI). Our aim was to investigate if the incidence and severity of thyroid damage increases in time.</p> </sec> <sec id="pbc24681-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>All long‐term survivors of childhood NBL treated with <sup>131</sup>I‐MIBG in the period 1989–1999 in our center (n = 16 of 43) were evaluated. During exposure to <sup>131</sup>I‐MIBG, patients received 100 mg KI per day as thyroid protection. All MIBG images were evaluated for thyroid uptake of radio‐iodine. Thyroid dysfunction was defined as a plasma thyrotropin concentration above the institutional age‐related reference ranges (thyrotropin elevation, TE) or using thyroxine at last moment of follow‐up. In all, ultrasound investigation of the thyroid was performed.</p> </sec> <sec id="pbc24681-sec-0003" sec-type="section"> <title>Results</title> <p>Fifteen years after treatment with <sup>131</sup>I‐MIBG, in 81% (n = 13) thyroid disorders were diagnosed. Eight survivors (50%) were treated with thyroxine. Thyroid nodules were found in nine survivors, of which two were diagnosed with papillary thyroid carcinoma. In 28% of<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24681-sec-0001" sec-type="section"> <title>Background</title> <p>Thyroid dysfunction has been reported in up to 52% of patients 1.4 years after treatment with <sup>131</sup>I‐Metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), despite the use of potassium‐iodide (KI). Our aim was to investigate if the incidence and severity of thyroid damage increases in time.</p> </sec> <sec id="pbc24681-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>All long‐term survivors of childhood NBL treated with <sup>131</sup>I‐MIBG in the period 1989–1999 in our center (n = 16 of 43) were evaluated. During exposure to <sup>131</sup>I‐MIBG, patients received 100 mg KI per day as thyroid protection. All MIBG images were evaluated for thyroid uptake of radio‐iodine. Thyroid dysfunction was defined as a plasma thyrotropin concentration above the institutional age‐related reference ranges (thyrotropin elevation, TE) or using thyroxine at last moment of follow‐up. In all, ultrasound investigation of the thyroid was performed.</p> </sec> <sec id="pbc24681-sec-0003" sec-type="section"> <title>Results</title> <p>Fifteen years after treatment with <sup>131</sup>I‐MIBG, in 81% (n = 13) thyroid disorders were diagnosed. Eight survivors (50%) were treated with thyroxine. Thyroid nodules were found in nine survivors, of which two were diagnosed with papillary thyroid carcinoma. In 28% of <sup>131</sup>I‐MIBG‐images radio‐iodine uptake in the thyroid gland was seen, but no correlation was found between thyroidal radio‐iodine uptake and thyroid disorders.</p> </sec> <sec id="pbc24681-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Despite protection with KI during exposure to <sup>131</sup>I‐MIBG in childhood, the occurrence of thyroid disorders is high and increases in time. Continuous screening for thyroid dysfunction and nodules in these survivors is recommended. Other ways to protect the thyroid gland should be further evaluated. Pediatr Blood Cancer 2013;60:1833–1838. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pediatric blood & cancer. Volume 60:Issue 11(2013:Nov.)
- Journal:
- Pediatric blood & cancer
- Issue:
- Volume 60:Issue 11(2013:Nov.)
- Issue Display:
- Volume 60, Issue 11 (2013)
- Year:
- 2013
- Volume:
- 60
- Issue:
- 11
- Issue Sort Value:
- 2013-0060-0011-0000
- Page Start:
- 1833
- Page End:
- 1838
- Publication Date:
- 2013-07-06
- Subjects:
- Tumors in children -- Periodicals
Blood -- Diseases -- Periodicals
Cancer in children -- Periodicals
618.92 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/pbc.24681 ↗
- Languages:
- English
- ISSNs:
- 1545-5009
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.533500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4293.xml